Patent intelligence · US
US 11590184
Oncolytic rhabdovirus expressing IL12
Oncolytic rhabdovirus expressing IL12
Patent details — US 11590184
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 28, 2023
- Expiration
- Feb 23, 2043
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Claims
- 34
- CPC classes
- A61K, A61K35/766, A61K35/768, A61K38/20
Quick answer
US 11590184 (Oncolytic rhabdovirus expressing IL12) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNSTONE LIMITED PARTNERSHIP
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K35/766, A61K35/768, A61K38/20, A61K38/208, A61K9/0019
More from TURNSTONE LIMITED PARTNERSHIP
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Related coverage
Frequently asked questions
What is US patent 11590184?
US 11590184 (Oncolytic rhabdovirus expressing IL12) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11590184?
TURNSTONE LIMITED PARTNERSHIP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11590184 expire?
Our index shows an expiration date of Feb 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.